Allergan builds case for migraine drug ubrogepant as FDA verdict nearsAllergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share XAllergan builds case for migraine drug ubrogepant as FDA verdict nearshttps://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/
FDA approves Lilly’s new migraine attack drug, rival from Allergan could followThe FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms Share XFDA approves Lilly’s new migraine attack drug, rival from Allergan could followhttps://pharmaphorum.com/news/fda-approves-lillys-new-migraine-attack-drug-rival-from-allergan-could-follow/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
Lundbeck to acquire Alder, and migraine drug, for $1.95bnLundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to Share XLundbeck to acquire Alder, and migraine drug, for $1.95bnhttps://pharmaphorum.com/news/lundbeck-to-acquire-alder-and-migraine-drug-for-1-95bn/
Lilly firms up case for Emgality in migraine market chaseEli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals, Share XLilly firms up case for Emgality in migraine market chasehttps://pharmaphorum.com/news/lilly-firms-up-case-for-emgality-in-migraine-market-chase/
Alder gears up for migraine showdown with eptinezumab filingAlder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of Share XAlder gears up for migraine showdown with eptinezumab filinghttps://pharmaphorum.com/news/alder-gears-up-for-migraine-showdown-with-eptinezumab-filing/
Scotland backs Aimovig for migraine after NICE says noPeople suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig Share XScotland backs Aimovig for migraine after NICE says nohttps://pharmaphorum.com/news/scotland-backs-aimovig-for-migraine-after-nice-says-no/
Novartis sues as Amgen tries to cancel migraine tie-upNovartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, Share XNovartis sues as Amgen tries to cancel migraine tie-uphttps://pharmaphorum.com/news/novartis-sues-as-amgen-tries-to-cancel-migraine-tie-up/
Teva’s migraine drug Ajovy approved in EuropeTeva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Share XTeva’s migraine drug Ajovy approved in Europehttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-approved-in-europe/
